Biopolymer-based functional composites for medical applications

SB Park, E Lih, KS Park, YK Joung, DK Han - Progress in Polymer Science, 2017 - Elsevier
Over the last decade, numerous biopolymers have received more attention in medical
applications involving novel biomaterials because of their biocompatibility, biodegradability …

Drug-releasing implants: current progress, challenges and perspectives

A Santos, MS Aw, M Bariana, T Kumeria… - Journal of Materials …, 2014 - pubs.rsc.org
The need for more efficient drug delivery strategies to treat resilient diseases and the rise of
micro and nanotechnology have led to the development of more sophisticated drug …

Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical …

PW Serruys, Y Onuma, D Dudek, PC Smits… - Journal of the American …, 2011 - jacc.org
Objectives: The aim of this study was to demonstrate that the prevention of early scaffold
area shrinkage of the ABSORB BVS (Rev. 1.1, Abbott Vascular, Santa Clara, California) was …

Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical …

PW Serruys, Y Onuma, JA Ormiston, B de Bruyne… - Circulation, 2010 - Am Heart Assoc
Background—The first generation of the bioresorbable everolimus drug-eluting vascular
scaffold showed signs of shrinkage at 6 months, which largely contributed to late luminal …

Long-Term (>10 Years) Clinical Outcomes of First-in-Human Biodegradable Poly-l-Lactic Acid Coronary Stents: Igaki-Tamai Stents

S Nishio, K Kosuga, K Igaki, M Okada, E Kyo, T Tsuji… - Circulation, 2012 - Am Heart Assoc
Background—The purpose of this study was to evaluate the long-term safety of the Igaki-
Tamai stent, the first-in-human fully biodegradable coronary stent made of poly-l-lactic acid …

First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study

JA Ormiston, PW Serruys, Y Onuma… - Circulation …, 2012 - Am Heart Assoc
Background—Nonserial observations have shown this bioresorbable scaffold to have no
signs of area reduction at 6 months and recovery of vasomotion at 1 year. Serial …

Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque …

S Brugaletta, JH Heo, HM Garcia-Garcia… - European heart …, 2012 - academic.oup.com
Aims To analyse the vasoreactivity of a coronary segment, previously scaffolded by the
ABSORB bioresorbable vascular scaffold (BVS) device, in relationship to its intravascular …

Assessing bioresorbable coronary devices: methods and parameters

HM Garcia-Garcia, PW Serruys, CM Campos… - JACC: Cardiovascular …, 2014 - jacc.org
Bioresorbable vascular scaffolds (BRS) represent a novel approach to provide transient
vessel support to drug-delivery capability without the long-term limitations of metallic drug …

[HTML][HTML] Bioresorbable vascular scaffold treatment induces the formation of neointimal cap that seals the underlying plaque without compromising the luminal …

CV Bourantas, PW Serruys… - …, 2015 - eurointervention.pcronline.com
Aims: To evaluate the implications of an Absorb bioresorbable vascular scaffold (Absorb
BVS) on the morphology of the superficial plaques. Methods and results: Forty-six patients …

Absorbable stent: focus on clinical applications and benefits

N Gonzalo, C Macaya - Vascular health and risk management, 2012 - Taylor & Francis
Coronary stents have improved very significantly the immediate and long-term results of
percutaneous coronary interventions. However, once the vessel has healed, the scaffolding …